Celldex Therapeutics Inc.
CLDX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.54B
Close$
$0.05
99.8% downside
Current Fair Value
99.8% downsideOvervalued by 99.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.54 Billion |
|---|---|
| Enterprise Value | $2.50 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.9 |
| Beta | 0.84 |
| Outstanding Shares | 77,840,000 |
Return
| Return on Equity | -42.07% |
|---|---|
| Return on Assets | -38.42% |
| Return on Invested Capital | -20.58% |
Valuation & Multiples
| P/E Ratio | -8.77 |
|---|---|
| PEG | -29.37 |
| Price to Sales | - |
| Price to Book Ratio | 3.5 |
| Enterprise Value to Revenue | 22338.22 |
| Enterprise Value to EBIT | -16.86 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.06
Average shareholder expectationRevenue Estimate
$734,917
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-1.02
Average shareholder expectationRevenue Estimate
$722,636
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.9281▲ 0.19% |
|---|---|
| Total Calls | 261,929▲ 164.84% |
| Total Puts | 505,019▲ 165.10% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 110.08%▲ 0.50% |
|---|---|
| Total Invested | $3.19B▲ 37.81% |
| Investors Holding | 270▲ 36.00% |
ESG Score
No data
About Celldex Therapeutics Inc.
CEO: Anthony Marucci Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeu...